Physician profile
Rachel Beth Ray
NPI 1336383322
$2,636.87
in general payments reported to CMS, 2019-2025
31 companies · $1,343 in 2025
The $1,343 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $273 · 2024: $1,021 · 2025: $1,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,636.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $539.76 | 2023-2025 | |
| Pfizer INC. | $491.54 | 2023-2025 | |
| Corium, LLC | $181.47 | 2024-2025 | Azstarys |
| Abbott Laboratories | $180.90 | 2024-2025 | Freestyle Libre 3 |
| Lundbeck LLC | $170.03 | 2024-2025 | Vyepti, Rexulti |
| Astrazeneca Pharmaceuticals LP | $121.83 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $107.89 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $81.95 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $69.86 | 2025 | Cologuard Collection Kit |
| Alk-Abello, INC | $63.76 | 2023-2024 | Odactra, Grastek, Ragwitek |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.90 | 2024-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $53.06 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Currax Pharmaceuticals LLC | $50.04 | 2024-2025 | Contrave, Onzetra Xsail |
| Takeda Pharmaceuticals U.S.A., INC. | $49.67 | 2024-2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $46.33 | 2025 | Jornay Pm |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $41.44 | 2025 | |
| Astellas Pharma US INC | $39.37 | 2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $35.96 | 2025 | |
| Phathom Pharmaceuticals, INC. | $28.66 | 2024-2025 | Voquezna |
| Dexcom, INC. | $25.01 | 2025 | Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $23.92 | 2023 | Jornay Pm |
| Electromed, INC. | $22.35 | 2025 | Smartvest |
| Aimmune Therapeutics, INC. | $21.71 | 2025 | Zenpep |
| Hologic Sales and Service, LLC | $20.79 | 2024 | Aptima |
| Insulet Corporation | $20.58 | 2023 | Omnipod |
| Teva Pharmaceuticals USA, INC. | $18.49 | 2023 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $17.28 | 2023 | Rexulti |
| Axsome Therapeutics, INC. | $15.75 | 2025 | Symbravo |
| Amgen INC. | $15.20 | 2023 | Otezla, Repatha |
| Paratek Pharmaceuticals, INC. | $14.49 | 2025 | Nuzyra |
| Tris Pharma INC | $12.88 | 2023 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.